CN110564686A - composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use - Google Patents
composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use Download PDFInfo
- Publication number
- CN110564686A CN110564686A CN201911068764.3A CN201911068764A CN110564686A CN 110564686 A CN110564686 A CN 110564686A CN 201911068764 A CN201911068764 A CN 201911068764A CN 110564686 A CN110564686 A CN 110564686A
- Authority
- CN
- China
- Prior art keywords
- hematopoietic stem
- stem cells
- cells
- composition
- jnk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 27
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 27
- 229960002930 sirolimus Drugs 0.000 claims abstract description 27
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 claims abstract description 25
- GJFCSAPFHAXMSF-UXBLZVDNSA-N 3-[[(e)-4-(dimethylamino)but-2-enoyl]amino]-n-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical compound CN(C)C\C=C\C(=O)NC1=CC=CC(C(=O)NC=2C=C(C)C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)=CC=2)=C1 GJFCSAPFHAXMSF-UXBLZVDNSA-N 0.000 claims abstract description 20
- 230000003321 amplification Effects 0.000 claims abstract description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000019491 signal transduction Effects 0.000 claims description 24
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 22
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 22
- 210000004700 fetal blood Anatomy 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 12
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000011435 rock Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 9
- 102000018697 Membrane Proteins Human genes 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 102000036693 Thrombopoietin Human genes 0.000 claims description 7
- 108010041111 Thrombopoietin Proteins 0.000 claims description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 5
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 5
- 230000037353 metabolic pathway Effects 0.000 claims description 5
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims description 4
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000003915 cell function Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 20
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 230000014509 gene expression Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 210000003995 blood forming stem cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- -1 small molecule compounds Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- AZXXGVPWWKWGAE-UHFFFAOYSA-N 4-n-[2-benzyl-7-(2-methyltetrazol-5-yl)-9h-pyrimido[4,5-b]indol-4-yl]cyclohexane-1,4-diamine Chemical compound CN1N=NC(C=2C=C3C(C4=C(NC5CCC(N)CC5)N=C(CC=5C=CC=CC=5)N=C4N3)=CC=2)=N1 AZXXGVPWWKWGAE-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a composition for amplifying hematopoietic stem cells, an amplification method, a pharmaceutical composition and application, wherein the composition consists of JNK-IN-8, rapamycin and Y27632. The composition can be used for efficiently amplifying the hematopoietic stem cells, effectively maintaining the protein phenotype and the gene expression profile of the hematopoietic stem cells, improving the in-vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and has important scientific research, clinical research and application values.
Description
Technical Field
The invention relates to the field of biomedicine. In particular, the invention relates to the use of the composition for expanding hematopoietic stem cells.
Background
The hematopoietic stem cell transplantation technology is a common and effective treatment means for clinically treating various blood diseases and immune system diseases such as leukemia, lymphoma, aplastic anemia, thalassemia and the like. Hematopoietic stem cells are generally derived from three sources: bone marrow, peripheral blood and cord blood. Compared with bone marrow and peripheral blood hematopoietic stem cells, the umbilical cord blood hematopoietic stem cells are convenient to obtain, rich in sources, free of damage and side effects on donors, and therefore become an important source of hematopoietic stem cell transplantation donors.
At present, the bottleneck of cord blood hematopoietic stem cell transplantation technology is that the cell content is low, and the number of hematopoietic stem cells and progenitor cells contained in one cord blood is not enough to quickly restore the immune system of an adult patient, so that the fatality rate of opportunistic infection is increased. The current tentative strategy is transplantation of two umbilical cord blood, i.e. one patient receives transplantation of two umbilical cord blood after marrow removal, but this increases the difficulty of matching HLA of donors, so a method for amplifying umbilical cord blood hematopoietic stem cells is urgently needed to obtain sufficient hematopoietic stem cells for transplantation.
Therefore, how to effectively obtain enough hematopoietic stem cells in vitro becomes a scientific problem, and if the technical bottleneck can be broken through in the future, a new chapter of clinical application of the stem cells will be written.
Currently, the most important factor limiting the clinical use of hematopoietic stem cells is the insufficient number of HSCs. There are roughly three strategies to solve this problem: (1) directly differentiating by iPSC or ESC to obtain HSCs with functions; (2) obtaining HSCs by cell reprogramming; (3) existing HSCs are expanded in vitro. The two methods involve excessive technical difficulty and cause additional risks for clinical application, so that clinical research cannot be carried out at a later date. The expansion of hematopoietic stem cells in vitro is an important method for solving the problem.
The in vitro expansion of hematopoietic stem cells has many advantages, which are mainly summarized as the following three characteristics: (1) the homogeneity of the expanded cells is high, and the canceration risk is low; (2) the operation time for expanding HSC is relatively short, and more exogenous adverse factors are prevented from being introduced; (3) the starting cells are hematopoietic stem/progenitor cells, generally have no risk of causing tumor, and are safer in clinical application.
the studies of amplified HSCs can be broadly divided into two categories: (1) amplifying HSCs by using gene manipulation means such as introducing exogenous transcription factors or micro RNA; (2) HSCs are amplified by adopting chemical micromolecules. In recent years, with the continuous progress of chemical small molecule technology, small molecule compounds have been widely used in the field of stem cell research. The amplification of HSCs using small molecule drugs has a number of distinct advantages: low toxicity, easy elution and safer clinical use. However, there are also significant disadvantages, and the most worrying is that the target of action of small molecule compounds is not well defined, and there may be safety hazards, such as off-target effect of small molecules, so there still exists a lack of a safe and effective chemical small molecule combination scheme for expanding hematopoietic stem cells with well-defined target in clinic.
In summary, the technical scheme of using the combination of chemical small molecule compounds to expand hematopoietic stem cells in vitro is still under study.
Disclosure of Invention
the present invention aims to solve, at least to some extent, the technical problems of the prior art. Therefore, the invention finds some chemical small molecule compound combinations through a high-throughput screening platform, which not only can efficiently amplify the hematopoietic stem cells in vitro and effectively maintain the protein phenotype and the gene expression profile of the hematopoietic stem cells, but also can improve the in vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and has great scientific research, clinical research and application values.
In one aspect of the invention, the invention features a composition for expanding hematopoietic stem cells. According to an embodiment of the invention, the composition consists of JNK-IN-8, rapamycin, and Y27632.
JNK-IN-8 is a JNK signal pathway inhibitor, and the function of regulating and controlling a JNK signal pathway is realized by inhibiting c-Jun phosphorylation and gene transcription; rapamycin (Rapamycin) is an mTOR signaling pathway inhibitor useful for anti-aging and inhibiting tumor growth; y27632 is ROCK1 inhibitor, can be used for resisting aging, and has effect in maintaining stem cell activity.
The inventor adopts high-throughput screening to obtain a compound for efficiently amplifying hematopoietic stem cells, finds that 3 micromolecule compounds of JNK-IN-8, rapamycin and Y27632 have the effects of mutual matching and synergism, can efficiently amplify the hematopoietic stem cells, effectively maintains the protein phenotype and the gene expression profile of the hematopoietic stem cells, can improve the IN-vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and has great scientific research, clinical research and application values.
In another aspect of the invention, the invention features a medium for expanding hematopoietic stem cells. According to an embodiment of the invention, the medium comprises: a basal medium; and the composition for expanding hematopoietic stem cells as described above. Therefore, the culture medium provided by the embodiment of the invention can be used for efficiently amplifying the hematopoietic stem cells, effectively maintaining the protein phenotype and the gene expression profile of the hematopoietic stem cells, improving the in vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and has great scientific research, clinical research and application values.
according to an embodiment of the present invention, the above-mentioned culture medium may further have the following additional technical features:
according to the embodiment of the invention, the concentration of the JNK ~ IN ~ 8 is 1 ~ 5 mu M, the concentration of the rapamycin is 1 ~ 20 nM, and the concentration of the Y27632 is 1 ~ 20 mu M, according to the embodiment of the invention, the concentrations of the JNK ~ IN ~ 8, the rapamycin and the Y27632 are 2 mu M, 10nM, 10 mu M or 3.5 mu M, 15nM, 7 mu M or 1.5 mu M, 8nM and 15 mu M respectively, according to the embodiment of the invention, the concentration of the JNK ~ IN ~ 8 is 1 ~ 3 mu M, the concentration of the rapamycin is 6 ~ 15nM, and the concentration of the Y27632 is 5 ~ 15 mu M.
According to an embodiment of the invention, the basal medium is selected from the group consisting of StemBan SFEM medium containing Flt3 ligand, Thrombopoietin (TPO), stem cell growth factor (SCF), and Low Density Lipoprotein (LDL). Thus, the efficiency of amplification can be further improved by adding the above-mentioned factor to the StemBansfEM medium.
according to the embodiment of the invention, the concentration of the Flt3 ligand is 60- ~ ng/mL, the concentration of thrombopoietin is 20-50 ng/mL, the concentration of the stem cell factor is 60- ~ ng/mL, and the concentration of the low-density lipoprotein is 5-20 μ g/mL. according to the embodiment of the invention, the concentrations of Flt3 ligand, thrombopoietin, stem cell factor and low-density lipoprotein are ~ ng/mL, 50ng/mL, ~ ng/mL, 10 μ g/mL or 80ng/mL, 30ng/mL, 80ng/mL, 15 μ g/mL or 90ng/mL, 40ng/mL, 90ng/mL and 6 μ g/mL, respectively.
According to an embodiment of the invention, the invention proposes the use of JNK-IN-8, rapamycin and Y27632 IN the preparation of a composition or culture medium for the expansion of hematopoietic stem cells.
In yet another aspect of the present invention, the present invention provides a method for expanding hematopoietic stem cells. According to an embodiment of the invention, the method comprises: the following metabolic pathways of hematopoietic stem cells are inhibited using the compositions described above: JNK signal path, mTOR signal path and ROCK signal path. The inventor respectively carries out high-throughput screening analysis on a plurality of small molecular substances capable of inhibiting a JNK signal pathway, an mTOR signal pathway and a ROCK signal pathway, and finds that the combined use of the JNK-IN-8 (JNK signal pathway inhibitor), the rapamycin (mTOR signal pathway inhibitor) and the Y27632 (ROCK signal pathway inhibitor) 3 factor can efficiently amplify the hematopoietic stem cells, effectively maintain the protein phenotype and the gene expression spectrum of the hematopoietic stem cells, and can improve the IN-vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, the operation is simple and convenient, and the application prospect is wide.
According to an embodiment of the invention, the method comprises: will CD34＋The cells are cultured in the medium for expanding hematopoietic stem cells described above. Therefore, the method can further improve the amplification efficiency, effectively maintain the protein phenotype and the gene expression profile of the hematopoietic stem cells, improve the in vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, is simple and convenient to operate, and has wide application prospect.
according to an embodiment of the present invention, the CD34＋the cells are derived from bone marrow, liver, spleen, peripheral blood or umbilical cord blood.
in yet another aspect of the present invention, the present invention provides a kit for expanding hematopoietic stem cells. According to an embodiment of the invention, the kit comprises: the composition for expanding hematopoietic stem cells described above or the culture medium described above. Therefore, the kit provided by the embodiment of the invention can be used for efficiently amplifying the hematopoietic stem cells, effectively maintaining the protein phenotype and the gene expression profile of the hematopoietic stem cells, improving the in vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and has great scientific research, clinical research and application values.
In a further aspect of the invention, the invention proposes the use of a composition as hereinbefore described for the preparation of an inhibitor. According to an embodiment of the invention, the inhibitor is used for expanding hematopoietic stem cells, inhibiting the following metabolic pathways of hematopoietic stem cells: JNK signal path, mTOR signal path and ROCK signal path. As described above, JNK-IN-8, rapamycin and Y27632 can effectively inhibit a JNK signal pathway, an mTOR signal pathway and/or a ROCK signal pathway, thereby efficiently amplifying hematopoietic stem cells, effectively maintaining the protein phenotype and the gene expression profile of the hematopoietic stem cells, improving the IN vivo reconstruction function and the reconstruction efficiency of the hematopoietic stem cells, and having great scientific research, clinical research and application values.
in yet another aspect of the invention, a pharmaceutical composition is provided. According to an embodiment of the invention, the pharmaceutical composition comprises: a composition as hereinbefore described or a culture medium as hereinbefore described. As described above, the pharmaceutical composition according to the embodiment of the present invention can efficiently expand hematopoietic stem cells, and directly or indirectly administer the composition or the culture medium as a pharmaceutical composition into a body (animal or cell) to expand hematopoietic stem cells, or apply hematopoietic stem cells obtained by the method for expanding hematopoietic stem cells into a body, which has a good in vivo reconstitution function and reconstitution efficiency, can be widely used for the treatment of blood system diseases and autoimmune diseases, and has significant scientific research, clinical research and application values.
according to embodiments of the present invention, the pharmaceutical compositions of the present invention may be used in conjunction with conventional methods of treatment and/or therapy, or may be used separately from conventional methods of treatment and/or therapy. When the pharmaceutical compositions of the present invention are administered in combination therapy with other drugs, they may be administered to the individual sequentially or simultaneously. Alternatively, the pharmaceutical compositions of the present invention may also comprise a combination of a pharmaceutically acceptable carrier or pharmaceutically acceptable excipient and other therapeutic or prophylactic agents known in the art.
The term "administering" as used herein means introducing a predetermined amount of a substance into a patient by some suitable means. The mesenchymal stem cell of the present invention may be administered by any common route as long as it can reach the desired tissue. Various modes of administration are contemplated, including peritoneal, intravenous, intramuscular, subcutaneous, cortical, oral, topical, nasal, pulmonary and rectal, but the invention is not limited to these exemplified modes of administration.
In yet another aspect of the invention, a method of screening for a drug is provided. According to an embodiment of the invention, the method comprises: combining the candidate drug with CD34＋Culturing the cells; determining whether intracellular JNK signaling pathway, mTOR signaling pathway and ROCK signaling pathway are inhibited before and after culturing and/or whether cells are culturedWhether the surface proteins representing the functions of hematopoietic stem cells in cells before and after amplification and/or culture are consistent; when the JNK signaling pathway, mTOR signaling pathway, and ROCK signaling pathway are inhibited after culturing and/or the cells are expanded after culturing and/or surface proteins representing hematopoietic stem cell functions in the cells before and after culturing are consistent, is an indication that the candidate drug is the target drug, which is the composition or the culture medium as described above. As described above, the composition according to the embodiment of the present invention can inhibit the above three metabolic pathways, thereby having the effect of expanding hematopoietic stem cells. Meanwhile, the protein phenotype and the gene expression profile of the hematopoietic stem cells can be effectively maintained after amplification. Therefore, by adopting the method for screening the drug according to the embodiment of the invention, the composition of the invention or the culture medium or the drug containing the composition can be effectively screened, and the method has great scientific research, clinical research and application values.
In the present invention, "identity" is used in the broad sense to mean "identity" in which the surface proteins representing the functions of hematopoietic stem cells in cells before and after culture are identical "and since there are many surface proteins representing the functions of hematopoietic stem cells, all the surface proteins are identical to each other by at least 80%, 85%, 90%, 95%, 99% or 100% before and after culture, and are considered to be" identity ".
IN yet another aspect of the invention, the invention features the use of JNK-IN-8, rapamycin, and Y27632 for expanding hematopoietic stem cells. As described above, JNK-IN-8, rapamycin and Y27632 can efficiently amplify hematopoietic stem cells, effectively maintain the protein phenotype and gene expression profile of the hematopoietic stem cells, improve the IN vivo reconstruction function and reconstruction efficiency of the hematopoietic stem cells, and have significant scientific research, clinical research and application values.
additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
The foregoing and/or additional aspects and advantages of the present invention will become apparent and readily appreciated from the following description of the embodiments, taken IN conjunction with the accompanying drawings, wherein 3F is an experimental group comprising three small molecules, JNK-IN-8, rapamycin and Y27632, and wherein for convenience of description:
FIG. 1 shows a schematic flow diagram of a process for expanding hematopoietic stem cells according to an embodiment of the present invention;
FIG. 2 shows DMSO group CD34 according to an embodiment of the invention+Flow cytometric analysis after day 7 of cell culture;
FIG. 3 shows a 3F group CD34 according to an embodiment of the invention+flow cytometric analysis after day 7 of cell culture;
FIG. 4 shows a CD34 according to an embodiment of the invention+flow cytometric analysis after day 7 of cell culture;
Fig. 5 shows an analysis of cells of hematopoietic stem cells according to an example of the invention after culturing in medium containing different small molecule compounds (control group DMSO conditions,. P <0.01,. P < 0.0001);
FIG. 6 is a schematic diagram showing the analysis of the expansion result of hematopoietic stem cells 20 weeks after reconstitution of hematopoietic stem cells according to an embodiment of the present invention.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Example 1
In this example, hematopoietic stem cells were expanded as follows:
The operation flow is shown in fig. 1, and the specific steps are as follows:
1. Cord blood separation CD34+Cells
1) Collection of umbilical cord blood
Collecting blood from umbilical cord of fetus in sterile environment of operating room, storing in blood bag containing anticoagulant, temporarily storing in 4 deg.C microenvironment, and sending to laboratory within 24 hr.
2) isolation of monocytes in umbilical cord blood
a) In a sterile laboratory bench, the cord blood is transferred to a sterile culture flask prepared in advance, and the ratio of the blood: adding phosphate buffer solution with the volume of =1.2, and uniformly mixing;
b) slowly adding the diluted umbilical cord blood adherent to the wall into a 50ml centrifuge tube containing 15ml of human lymph separation liquid, and paying attention to the slow addition to keep the interface of the two liquid surfaces clear and not break the liquid surface balance between the blood and the lymph separation liquid;
c) Centrifuging at 1500 rpm for 20 min at room temperature;
d) After centrifugation, the liquid surface is divided into three layers, the uppermost layer is a plasma/tissue homogenate layer, the lowermost layer is red blood cells, the middle layer is a separation liquid, and a thin and dense white membrane, namely a monocyte layer (including lymphocytes and monocytes), is arranged between the plasma layer and the separation liquid layer. Carefully pipette the buffy coat cells into another 50ml centrifuge tube;
e) Diluting to 50ml volume with PBS, and mixing by inversion;
f) centrifugation at 1600 rpm for 10 minutes at room temperature;
g) The supernatant was discarded and resuspended in PBS for further use.
3) Magnetic bead sorting method for separating CD34+Cells
a) Mixing human CD34 magnetic beads with mononuclear cells separated from umbilical cord blood according to a certain proportion, uniformly blowing, placing in a refrigerator at 4 ℃ for standing for 30 minutes, simultaneously placing equipment required by magnetic bead sorting in a super clean bench, and irradiating with ultraviolet light for sterilization;
b) Adding 10ml PBS and mixing evenly, and centrifuging for 5 minutes at 1600 rpm;
c) Discarding the supernatant, resuspending with PBS containing 0.5% BSA, and preparing to pass through an adsorption column;
d) Rinsing the adsorption column with PBS containing 0.5% BSA, adding monocyte suspension, and waiting for the monocyte suspension to completely pass through the adsorption column;
e) the column was washed with 1ml PBS containing 0.5% BSA and repeated 3 times;
f) Transferring the adsorption column into a 15ml centrifuge tube, adding 1ml PBS containing 0.5% BSA onto the filter membrane of the adsorption column, and washing the cells carrying CD34 magnetic beads adsorbed on the filter membrane into the centrifuge tube;
g) Centrifuging, discarding the supernatant, and adding medium to resuspend CD34+A cell.
4) Flow analysis of CD34 in the resulting monocytes+in proportion of
a) Taking a small part of the obtained cells carrying the CD34 magnetic beads out to a 1.5ml centrifuge tube;
b) Adding corresponding surface protein antibody, standing in a refrigerator at 4 deg.C;
c) After 30 minutes, taking out, and adding 1ml of PBS;
d) 1600 revolutions per minute, centrifuging for 3 minutes;
e) the supernatant was discarded and resuspended in 200. mu.l of precooled PBS, and the phenotype of the cells obtained was analyzed and detected by a flow cytometer.
2、CD34+Cell culture method
1) Resuspension of CD34 with StemBan SFEM medium (Stemcell brand) containing SCF (100 ng/ml), Flt-3L (100 ng/ml), TPO (50 ng/ml), LDL (10. mu.g/ml)+Cells were added to a 6-well low-profile plate with a cell density of 1X 106the particle/ml is less than that of the traditional Chinese medicine,
Wherein the experimental group is hematopoietic stem cells (named as 3F group) obtained by adding 2 mu M JNK-IN-8, 10nM Rapamycin and 10 mu M Y27632 into the culture medium and culturing, the control group is hematopoietic stem cells (named as DMSO group) obtained by replacing 3 factors IN the experimental group with equal volume of DMSO, and the Fresh group is CD34 freshly separated from umbilical cord blood without IN vitro culture+A cell;
2) will CD34+cells were incubated at 37 ℃ with 5% CO2Culturing in a cell culture box;
3) Every 2 days, half of the culture medium replacement is carried out to ensure that the cell density is 1 multiplied by 106Particle/ml is below;
4) After a period of incubation, the cells are examined for phenotypic changes and the number of cells is counted.
The flow assay pattern at day 7 of cell culture is shown in FIGS. 2 and 3. It is found that hematopoietic stem cells can be efficiently expanded by using three factors, i.e., JNK-IN-8, Rapamycin and Y27632, and that the obtained hematopoietic stem cells have a good survival state and surface proteins representing the functions of hematopoietic stem cells can be maintained. CD34 in comparison to DMSO medium+CD45RA-CD38-CD90＋Cells can be expanded efficiently in factor 3 medium (fig. 4).
Example 2
In this example, the effect of different small molecule compounds on hematopoietic stem cell expansion was investigated, and a specific culture was performed as in example 1, except that different types of small molecule compounds were added to the medium.
FIG. 5 compares the effect of adding different factors to the medium on the efficiency of expansion of hematopoietic stem cells. Wherein J is JNK-IN-8, Y is Y27632, R is Rapamycin, N is NAD, V is valproic acid, JY is adding JNK-IN-8 and Y27632 simultaneously, RU is adding Rapamycin and UM171 simultaneously, YR is adding Y27632 and Rapamycin simultaneously, YU is adding Y27632 and UM171 simultaneously, JYR is adding JNK-IN-8, Rapamycin and Y27632 simultaneously, JRU is adding JNK-IN-8, Rapamycin and UM171 simultaneously, YRU is adding Y27632, Rapamycin and UM171 simultaneously.
As a result, it can be seen that 3 factors, namely JNK-IN-8, Y27632 and Rapamycin, are added simultaneously, CD34, compared with the addition of JNK-IN-8, Y27632 and Rapamycin alone or other factors+CD45RA-the expansion efficiency of the labeled hematopoietic stem progenitor cells is highest.
after 7 days of amplification, the cells are injected into NPG severe immunodeficiency mice through tail veins for 20 weeks, the expansion multiple of the hematopoietic stem cells cultured by the factor 3 is calculated by using a limiting dilution method, the left graph of FIG. 6 shows that the proportion of the hematopoietic stem cells in the cells amplified by the 3F culture condition is higher than that in DMSO and Fresh groups, 1 hematopoietic stem cell is present in each 486 cells on average in the cells cultured by the 3F culture condition after 7 days, while 1 hematopoietic stem cell is present in 4882 cells on average in the DMSO control group, and one hematopoietic stem cell is present in each 3909 cells on average in the Fresh control group, so that the 3F culture condition amplifies the number of the hematopoietic stem cells in the Fresh primary CD34+ cells by about 9 times according to statistical data.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A composition for expanding hematopoietic stem cells, comprising JNK-IN-8, rapamycin, and Y27632.
2. A medium for expanding hematopoietic stem cells, comprising:
a basal medium; and
The composition of claim 1.
3. the culture medium according to claim 2, wherein the concentration of JNK ~ IN ~ 8 is 1 ~ 5 μ M, the concentration of rapamycin is 1 ~ 20 nM, and the concentration of Y27632 is 1 ~ 20 μ M;
The basal medium is selected from StemBan SFEM medium containing Flt3 ligand, thrombopoietin, stem cell growth factor, and low density lipoprotein;
the concentration of the Flt3 ligand is 60 ~ 100ng/mL, the concentration of thrombopoietin is 20 ~ 50ng/mL, the concentration of stem cell factor is 60 ~ 100ng/mL, and the concentration of low ~ density lipoprotein is 5 ~ 20 mug/mL.
4. A method of expanding hematopoietic stem cells, comprising: the use of the composition of claim 1 to inhibit the following metabolic pathways of hematopoietic stem cells: JNK signal path, mTOR signal path and ROCK signal path.
5. the method of claim 4, wherein the method comprises: will CD34＋culturing the cells in the medium of claim 2 or 3;
the CD34＋the cells are derived from bone marrow, liver, spleen, peripheral blood or umbilical cord blood.
6. a kit for expanding hematopoietic stem cells, comprising: the composition of claim 1 or the culture medium of claim 2 or 3.
7. use of the composition of claim 1 for the preparation of an inhibitor for the expansion of hematopoietic stem cells, for the inhibition of the following metabolic pathways of hematopoietic stem cells:
JNK signal path, mTOR signal path and ROCK signal path.
8. A pharmaceutical composition, comprising: the composition of claim 1 or the culture medium of claim 2 or 3.
9. a method of screening for a drug comprising:
combining the candidate drug with CD34＋Culturing the cells;
Determining whether a JNK signal pathway, an mTOR signal pathway and a ROCK signal pathway in the cells before and after culture are inhibited and/or whether the cells after culture are amplified and/or whether surface proteins representing the functions of hematopoietic stem cells in the cells before and after culture are consistent;
When the JNK signal pathway, the mTOR signal pathway and the ROCK signal pathway are inhibited after culture and/or after culture, cell amplification and/or surface proteins representing hematopoietic stem cell functions in cells before and after culture are consistent, the indication that the candidate drug is the target drug,
the target drug is the composition of claim 1 or the culture medium of claim 2 or 3.
Use of JNK-IN-8, rapamycin and Y27632 for expanding hematopoietic stem cells.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911068764.3A CN110564686B (en) | 2019-11-05 | 2019-11-05 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use |
| PCT/CN2020/080029 WO2021088293A1 (en) | 2019-11-05 | 2020-03-18 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical compositions and uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911068764.3A CN110564686B (en) | 2019-11-05 | 2019-11-05 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110564686A true CN110564686A (en) | 2019-12-13 |
| CN110564686B CN110564686B (en) | 2020-04-03 |
Family
ID=68786081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911068764.3A Active CN110564686B (en) | 2019-11-05 | 2019-11-05 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110564686B (en) |
| WO (1) | WO2021088293A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021088293A1 (en) * | 2019-11-05 | 2021-05-14 | 诺未科技（北京）有限公司 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical compositions and uses |
| CN113088491A (en) * | 2021-04-01 | 2021-07-09 | 保定诺未科技有限公司 | Method for promoting up-regulation of FOXO1 gene expression in hematopoietic stem cells |
| WO2022148015A1 (en) * | 2021-01-09 | 2022-07-14 | Susheng Biotech (Hainan) Co., Ltd. | Signaling pathway inhibitor and drug for up-regulating mllt3 gene expression in hematopoietic stem cells, and use of signaling pathway inhibitor |
| CN114958744A (en) * | 2022-07-12 | 2022-08-30 | 上海派思维新生物医药科技有限公司 | In-vitro stem cell expanded culture method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108235708A (en) * | 2017-12-29 | 2018-06-29 | 罗小霞 | Cultivating system and its method, the candidate stem cell and hematopoietic progenitor cells of amplifying candidate stem cell and/or hematopoietic progenitor cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108300695B (en) * | 2018-02-07 | 2021-08-06 | 清华大学 | Method for differentiating human pluripotent stem cells into hematopoietic stem cells and culture additive |
| CN110564687B (en) * | 2019-11-05 | 2020-04-03 | 诺未科技（北京）有限公司 | Compositions, media, methods and kits for expanding hematopoietic stem cells |
| CN110564686B (en) * | 2019-11-05 | 2020-04-03 | 诺未科技（北京）有限公司 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use |
| CN110669732B (en) * | 2019-11-05 | 2021-05-04 | 清华大学 | Use of compositions for reprogramming hematopoietic progenitor cells to hematopoietic stem cells |
-
2019
- 2019-11-05 CN CN201911068764.3A patent/CN110564686B/en active Active
-
2020
- 2020-03-18 WO PCT/CN2020/080029 patent/WO2021088293A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108235708A (en) * | 2017-12-29 | 2018-06-29 | 罗小霞 | Cultivating system and its method, the candidate stem cell and hematopoietic progenitor cells of amplifying candidate stem cell and/or hematopoietic progenitor cells |
Non-Patent Citations (2)
| Title |
|---|
| KALAMEGAM GAUTHAMAN等: "Effect of ROCK Inhibitor Y-27632 on Normal and Variant Human Embryonic Stem Cells (hESCs) In Vitro: Its Benefits in hESC Expansion", 《STEM CELL REV AND REP》 * |
| 李晓毅: "抑制P38MAPK、mTORC1和AHR信号促进人脐带血HSCs扩增并维持干性", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021088293A1 (en) * | 2019-11-05 | 2021-05-14 | 诺未科技（北京）有限公司 | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical compositions and uses |
| WO2022148015A1 (en) * | 2021-01-09 | 2022-07-14 | Susheng Biotech (Hainan) Co., Ltd. | Signaling pathway inhibitor and drug for up-regulating mllt3 gene expression in hematopoietic stem cells, and use of signaling pathway inhibitor |
| CN113088491A (en) * | 2021-04-01 | 2021-07-09 | 保定诺未科技有限公司 | Method for promoting up-regulation of FOXO1 gene expression in hematopoietic stem cells |
| CN113088491B (en) * | 2021-04-01 | 2022-11-29 | 保定诺未科技有限公司 | Method for promoting up-regulation of FOXO1 gene expression in hematopoietic stem cells |
| CN114958744A (en) * | 2022-07-12 | 2022-08-30 | 上海派思维新生物医药科技有限公司 | In-vitro stem cell expanded culture method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110564686B (en) | 2020-04-03 |
| WO2021088293A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110564686B (en) | Composition for expanding hematopoietic stem cells, expansion method, pharmaceutical composition and use | |
| CN110564687B (en) | Compositions, media, methods and kits for expanding hematopoietic stem cells | |
| US7919316B2 (en) | Hematopoietic stem cell identification and isolation | |
| WO2019080920A1 (en) | Method for increasing fetal hemoglobin expression level | |
| RU2757818C2 (en) | Methods and compositions for stem cell transplantation | |
| TW201130978A (en) | Method of isolation of stem cell populations from peripheral blood using sized-based separation (elutriation) | |
| CN111040997A (en) | Prostate cancer organoid culture and cryopreservation method with tumor immune microenvironment | |
| RU2756000C2 (en) | Method for the production of platelets by a method for rotational mixing of the culture | |
| CN110669732B (en) | Use of compositions for reprogramming hematopoietic progenitor cells to hematopoietic stem cells | |
| Niazi et al. | Hypoxia preconditioned mesenchymal stem cell‐derived exosomes induce ex vivo expansion of umbilical cord blood hematopoietic stem cells CD133+ by stimulation of Notch signaling pathway | |
| CN113583947B (en) | Mesenchymal stem cell and hematopoietic stem cell in vitro culture method and system | |
| CN111424015A (en) | Culture medium and three-dimensional culture method for prostate tumor cells | |
| CN110713979B (en) | Culture method of CD34+ hematopoietic stem cells | |
| Sun et al. | Isolation of mouse mammary carcinoma-derived macrophages and cancer cells for co-culture assays | |
| CN112048474B (en) | Method for enhancing hematopoietic stem cell transplantation capability | |
| CN115340981A (en) | Culture medium for in-vitro amplification of cord blood CD34 positive hematopoietic stem cells | |
| US20090298045A1 (en) | Method For Selectively Expanding, Selecting And Enriching Stem/Progenitor Cell Populations | |
| Mobaraki et al. | Evaluation of expansion and maintenance of umbilical cord blood CD34+ cells in the co-culture with umbilical cord blood-derived mesenchymal stem cells in the presence of microcarrier beads | |
| EP3943932A1 (en) | Method for providing immune cells | |
| JP2022502080A (en) | WNT-Activated Adipose-Derived Stem Cell Devices, Methods and Systems | |
| Vang et al. | Expansion and cellular characterization of primary human adherent cells in the Quantum® Cell Expansion System, a hollow-fiber bioreactor system | |
| EP4190892A1 (en) | Platelet lysate derived from autologous platelets | |
| CN109593716B (en) | Culture system and method for expanding hematopoietic stem cells and application thereof | |
| Farhat et al. | Effects of Asphyxia on Colony-forming Ability of Hematopoietic Stem Cell of Cord Blood. | |
| CN115896021A (en) | Molecular marker of human megakaryocyte biased hematopoietic stem cells and detection kit thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40014873 Country of ref document: HK |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20230524 Address after: Room B218, 2nd Floor, Building B, No. 18 West Ring South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: Saidete (Beijing) Bioengineering Co.,Ltd. Address before: 100176 Beijing Beijing economic and Technological Development Zone, 18 South West Road, block B, 1 floor, 103 room. Patentee before: NEWISH TECHNOLOGY (BEIJING) Co.,Ltd. |
|
| TR01 | Transfer of patent right |